Alisertib is an oral AURKA inhibitor that, as a single agent, showed beneficial activity in a phase II trial in terms of ORR (21%, 10/48 pts) in relapsed or refractory SCLC [98]. The gene discussed is AURKA; the disease is small cell lung carcinoma.